Hormonal
GLP-1 receptor agonists (GLP-1RA) and dual GLP-1/GIP agonists significantly reduce major adverse cardiovascular events (MACE), with weight loss acting as the predominant mediator of this benefit compared to blood pressure reduction alone.
If you have type 2 diabetes or obesity and are at high cardiovascular risk, GLP-1RA medications can significantly lower your risk of heart attacks and strokes. The benefit comes largely from the weight loss these drugs cause, rather than just lowering blood pressure. Discuss these options with your doctor, especially if you have resistant hypertension.
While both parameters were associated with cardiovascular benefit, the association with weight loss was statistically significant and stronger (R = 0.72, p = 0.019), whereas SBP reduction showed a weaker, non-significant correlation (R = 0.51, p = 0.123). These findings suggest that weight loss may be the predominant driver of cardiovascular protection in this setting, although BP lowering may act synergistically.
Why this rating
Meta-analysis of 10 RCTs with 145,322 participants, though limited by ecological bias in meta-regression.
Source
Ambulatory BP and Weight Reduction as Predictors of GLP-1RA CV Benefit
Nicolás Renna et al. · medRxiv · 2025
DOI 10.1101/2025.06.12.25329536
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →